SLex Antigen Inhibitor Development Service

SLex Antigen Inhibitor Development Service

Sialyl-Lewis X (SLex) Antigen Inhibitor Development Service at CD BioGlyco

SLex is a salivary lase-acidified polytetrasaccharide that is an endogenous antigen. It occurs highly expressed in the cells of many epithelial tumors. In turn, SLex antigen inhibitors interfere with the proliferation and differentiation of certain tumor cells. Therefore, research on the development of SLex antigen inhibitors is of great importance in glycobiology. At CD BioGlyco, we offer SLex antigen inhibitor development services.

  • SLex antibody development service

SLex antibodies have the specificity to recognize SLex antigens and can bind as well as clear SLex antigens. We offer a variety of tools to develop SLex antibodies:

  • Hybridoma technology: We use animal models to produce monoclonal antibodies by fusing sensitized B cells, which secrete specific antibodies, and myeloma cells, which can multiply indefinitely, into hybridoma cells through a process of animal immunization, cell fusion, hybridoma, and subclonal screening. This technique produces highly homogeneous SLex antibodies directed only against specific SLex antigens.
  • Antibody library screening technology: Utilizing the SLex antibody library, we perform incubation experiments after gradient dilution of SLex antigen to observe the expression effect of SLex antigen. We perform a total of three rounds of screening, and each round of elution is followed by titer measurement. Finally, we compare with the control group to screen out reliable antibodies to the SLex antigen.
  • Small molecule-based SLex antigen inhibitor development service
    We provide high-throughput screening combined with fluorescent labeling of biological small molecules that interfere with the synthesis of SLex antigens. Then, we derivatize and modify the screened small molecules and evaluate their effectiveness in inhibiting SLex antigens. Finally, their inhibitory activities are compared to obtain small molecule inhibitors of SLex antigen.

Fig.1 SLex antigen inhibitor development service. (CD BioGlyco)Fig.1 SLex antigen inhibitor development service. (CD BioGlyco)


Journal: Journal of Chemical Information and Modeling

IF: 5.6

Published: 2021

Results: Selectins interact with cell surface glycans to promote initial leukocyte bundling and rolling, and these interactions are the targets for the design of inhibitors. The heterodimeric endogenous tetrasaccharides, SLex and SLea are the minimal glycan structures required for selectin binding. Understanding their subtle structural differences is beneficial for the rational design of the corresponding inhibitors. Crystal structures based on modeling of E-selectin-SLex suggest that the N-acetyl group of GlcNAc in SLex can form a spatial site barrier in the E-selectin-SLex complex, but the hydroxy methylene group of GlcNAc in sLe permits stronger binding interactions at the same position. Subsequently designed inhibitors with synthetic accessible junction molecules that did not displace the exocyclic portion of GlcNAc showed dynamic and energetic binding characteristics comparable to those of SLea. The inhibitors were also designed to be able to bind to GlcNAc in the SLea complex.


  • The development of SLex antigen inhibitors can be used to develop antiviral and anti-cancer agents.
  • The development of SLex antigen inhibitors drives innovation in the field of carbohydrate-based vaccines.
  • The development of SLex antigen inhibitors can be used in therapeutic studies of tumors.


  • Our antigen research and development team provides our clients with custom production solutions according to their requirements.
  • Our service team is responsive and proactive to ensure a positive client experience and satisfaction.
  • We have high-quality, efficient, and stable antigen inhibitor development technology.

CD BioGlyco has extensive experience in glycobiology research. We have developed a dependable Glycosylation Inhibitor Development Service to assist our clients in solving their glycosylation challenges. If you are interested in our services, please contact us for more details without any hesitation.


  1. Mondal, N.; et al. Distinct human α(1,3)-fucosyltransferases drive Lewis-X/sialyl Lewis-X assembly in human cells. Journal of Biological Chemistry. 2018, 293(19): 7300-7314.
  2. Hu, Z.C.; et al. Insights into selectin inhibitor design from endogenous isomeric ligands of SLea and SLex. Journal of Chemical Information and Modeling. 2021, 61(12): 6085-6093.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.